Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study
Authors' conclusion
Body weight emerges as the primary covariate over pharmacogenetic variants in PPK modelling of MPA in paediatric LN.
Study context
- Population
- Paediatric patients with lupus nephritis (LN) receiving mycophenolate mofetil (MMF)146 AUC values
- Participants
- 51 patients
- Outcome
- MPA PK and covariates
- Follow-up
- Steady state (at least 7 days)
Methodological detailstwo-compartment PPK model (Phoenix NLME), internal and external validation
- Two-compartment PPK model (Phoenix NLME)
- Internal and external validation
Main finding
As reported in the abstract
steady state (at least 7 days)
Mean AUC
31.05 μg×hour/mL
Mean clearance
11.10 L/hour
Genetic variants in UGT1A9, ABCC2 and CES1 significantly impacting mycophenolic acid (MPA) AUC (of 29 SNPs across 13 candidate genes)
8
Observational data: associations, not effects.
Further findings
External validation (9 patients)
- Strong predictive performance
Original publication
Impact of body weight on mycophenolic acid population pharmacokinetics in paediatric lupus nephritis: a pharmacogenomic integration study. Lupus Sci Med. Published 1 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →